ASK 8007

Drug Profile

ASK 8007

Alternative Names: ASK8007

Latest Information Update: 10 Dec 2010

Price : $50

At a glance

  • Originator Immuno-Biological Laboratories
  • Developer Astellas Pharma; Kaketsuken
  • Class Anti-inflammatories; Antirheumatics; Glycoproteins; Monoclonal antibodies
  • Mechanism of Action Osteopontin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Bone disorders; Cancer; Rheumatoid arthritis

Most Recent Events

  • 28 Mar 2006 Preclinical trials in Cancer in Japan (unspecified route)
  • 28 Mar 2006 Preclinical trials in Bone disorders in Japan (unspecified route)
  • 28 Mar 2006 Preclinical trials in Rheumatoid arthritis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top